Combination of ibrutinib with ABT-199: Synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways

British Journal of Haematology

Volumn 168, Issue 5, 2015, Pages 765-768

  Zhao, Xiaoxian ^a   Bodo, Juraj ^a   Sun, Danyu ^b   Durkin, Lisa ^a   Lin, Jeffrey ^a   Smith, Mitchell R ^b   Hsi, Eric D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; BCL 2; Bruton tyrosine kinase; Mantle cell lymphoma; Synergy

Indexed keywords

BRUTON TYROSINE KINASE; CASPASE; IBRUTINIB; MEMBRANE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL 2L1; PROTEIN KINASE B; PROTEIN MCL 1; UNCLASSIFIED DRUG; VENETOCLAX; AGAMMAGLOBULINAEMIA TYROSINE KINASE; ANTINEOPLASTIC AGENT; BCL2 PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CCMCL1 CELL LINE; CELL SPECIFICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME DEGRADATION; IMMUNOBLOTTING; JEKO 1 CELL LINE; JVM2 CELL LINE; LYMPHOMA CELL LINE; MANTLE CELL LYMPHOMA; MINO CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN ANALYSIS; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; REC 1 CELL LINE; SIGNAL TRANSDUCTION; AGONISTS; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; LYMPHOMA, MANTLE-CELL; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; HUMANS; LYMPHOMA, MANTLE-CELL; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 84922787400     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13149     Document Type: Article

References (10)

1. Axelrod, M., Ou, Z., Brett, L.K., Zhang, L., Lopez, E.R., Tamayo, A.T., Gordon, V., Ford, R.J., Williams, M.E., Pham, L.V., Weber, M.J. & Wang, M.L. (2014) Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma. Leukemia, 28, 407-410.
2. Blois, J.T., Mataraza, J.M., Mecklenbrauker, I., Tarakhovsky, A. & Chiles, T.C. (2004) B cell receptor-induced cAMP-response element-binding protein activation in B lymphocytes requires novel protein kinase Cdelta. Journal of Biological Chemistry, 279, 30123-30132.
3. Chen, S., Dai, Y., Harada, H., Dent, P. & Grant, S. (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Research, 67, 782-791.
4. Davis, R.E., Ngo, V.N., Lenz, G., Tolar, P., Young, R.M., Romesser, P.B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., Xu, W., Shaffer, A.L., Wright, G., Xiao, W., Powell, J., Jiang, J.K., Thomas, C.J., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Gascoyne, R.D., Connors, J.M., Johnson, N.A., Rimsza, L.M., Campo, E., Jaffe, E.S., Wilson, W.H., Delabie, J., Smeland, E.B., Fisher, R.I., Braziel, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C., Pierce, S.K. & Staudt, L.M. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature, 463, 88-92.
5. Fresquet, V., Rieger, M., Carolis, C., Garcia-Barchino, M.J. & Martinez-Climent, J.A. (2014) Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood, 123, 4111-4119.
6. Garraway, L.A. & Janne, P.A. (2012) Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discovery, 2, 214-226.
7. Wang, M.L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B.S., Jurczak, W., Advani, R.H., Romaguera, J.E., Williams, M.E., Barrientos, J.C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W.W., Johnson, P., Spurgeon, S.E., Li, L., Zhang, L., Newberry, K., Ou, Z., Cheng, N., Fang, B., McGreivy, J., Clow, F., Buggy, J.J., Chang, B.Y., Beaupre, D.M., Kunkel, L.A. & Blum, K.A. (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. New England Journal of Medicine, 369, 507-516.
8. Wilson, B.E., Mochon, E. & Boxer, L.M. (1996) Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Molecular and Cellular Biology, 16, 5546-5556.
9. Zhao, X., Bodo, J., Sun, D., Durkin, L., Lin, J., Shetty, S., Smith, M.R. & Hsi, E.D. (2013) Combination of ibrutinib with ABT-199, a BCL-2 pathway inhibitor: effective therapeutic strategy in a novel mantle cell lymphoma cell line model. Blood, (ASH Annual Meeting Abstracts), 122, 645.
10. Zucca, E. & Bertoni, F. (2013) Toward new treatments for mantle-cell lymphoma?. The New England Journal of Medicine, 369, 571-572.